Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Conditions: Pancreatic Cancer; Breast Cancer; Gastric Cancer; Non-small Cell Lung Cancer; Cervical Cancer; Endocervical Cancer; Squamous Cell Carcinoma of Head and Neck; Bladder Urothelial Cancer; Colorectal Carcinoma; Esophageal Cancer; Ovarian Cancer; Re nal Cell Carcinoma; Prostate Cancer; Melanoma; Mesothelioma; Cholangiocarcinoma Interventions: Drug: NGM831; Drug: NGM831 plus pembrolizumab Sponsor: NGM Biopharmaceuticals, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Asbestosis | Bile Duct Cancer | Cancer | Cancer & Oncology | Carcinoma | Cholangiocarcinoma | Gastroenterology | Melanoma | Mesothelioma | Research | Skin Cancer | Study